buyModerate
Ra Capital Management, L.p. bought $100M of CDTX
director, owner at Cidara Therapeutics, Inc.. 2,272,727 shares at an average of $44.00, traded Jun 26, 2025, filed Jun 30, 2025.
Conviction score
50Value
$100M
2,272,727 shares
Holdings after
3,365,523
+208% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleDirector
- +25Trade size$100.0M at market
- +10Relative to holdingsHoldings up 208%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001415889-25-018516, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 26, 2025 | POpen-market purchase Common Stockindirect: See footnotes | +2,272,727 | $44.00 | $100M | 3,365,523 | Jun 30, 2025 |
Related signals
Other insiders at Cidara Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 43Moderate | CDTXbuy Cidara Therapeutics, Inc. | Jeffrey Stein President & CEO | $339k 4,262 shares | +7% | |
| 40Moderate | CDTXsell Cidara Therapeutics, Inc. | Shane Ward COO & CLO | $2.2M 9,959 shares | -28% | |
| 20Weak | CDTXsell Cidara Therapeutics, Inc. | Nicole Negar Davarpanah Chief Medical Officer | $30k 474 shares | -1% | |
| 31Weak | CDTXbuy Cidara Therapeutics, Inc. | Chrysa Mineo director | $74k 3,320 shares | - | |
| 29Weak | Cidara Therapeutics, Inc. | Leslie Tari CHIEF SCIENTIFIC OFFICER | $39k 1,773 shares | -10% | |
| 39Weak | Cidara Therapeutics, Inc. | Shane Ward COO & CLO | $37k 1,664 shares | -10% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.